Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Translational research

5385 - A Systematic Rapid Autopsy Program Tracks Temporal and Spatial Heterogeneity of Human Tumors and Identifies Mechanisms of Resistance to Targeted Therapies


09 Sep 2017


Translational research


Translational Research


Charlotte Walmsley


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


C.S. Walmsley1, D. Juric1, A. Bardia1, L. Henderson1, J. Gurski1, J.R. Stone2, C. Pinto1, S.J. Isakoff1, D.M. Fitzgerald1, J.F. Gainor1, L. Goyal1, M. Broudo1

Author affiliations

  • 1 Termeer Center For Targeted Therapies, Massachusetts General Hospital Cancer Center, 02114 - Boston/US
  • 2 Department Of Pathology, Massachusetts General Hospital, Boston, MA/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5385


Temporal and spatial heterogeneity of human tumors pose a significant barrier in the identification of effective anticancer therapies. Rapid autopsy, defined as post-mortem examination with collection of tissues for diagnosis and research within 6 hours of death, is a critical tool offering insight into this phenomenon.


Since January 2014, an on-call rapid autopsy team consisting of a pathologist, medical oncologist, pathology assistant and a tissue collection coordinator performed rapid autopsies on 51 patients with genomically-defined advanced solid tumors. Samples were collected from the primary tumor when present, multiple metastatic lesions, blood, as well as multiple uninvolved sites. All samples were recorded in a centralized database linked to patient’s treatment history, as well as all previously collected tissue and liquid biopsies, under one clinical data and sample collection protocol. Samples meeting minimum viability and tumor cellularity criteria were selected for downstream analyses, including next-generation sequencing and protein-based assays.


In 51 rapid autopsies, a median of 12 tissue samples were collected per autopsy (range 5-24), after a median of 2 hours and 50 minutes post mortem (range 32 minutes - 9 hours). 47 autopsies (92.2%) were completed < 6 hours post mortem, and 4 autopsies (7.8%) were completed > 6 hours post mortem due to delays in the confirmation of the autopsy consent from the patient’s healthcare proxy and transportation delays. Tumor cellularity of collected samples ranged from 0-90% (median 60%), making these samples highly suitable for subsequent genomic analyses. Full analysis of 3 autopsy series revealed molecular alterations driving resistance to PI3K-alpha inhibitors, CDK4/6 inhibitors and FGFR inhibitors in patients with PIK3CA-altered metastatic breast cancer and FGFR2 fusion positive cholangiocarcinoma.


Rapid autopsies complement serially collected tissue and liquid biopsies, providing invaluable samples for analysis of tumor heterogeneity, evolutionary dynamics and determination of resistance mechanisms to targeted therapies.

Clinical trial identification

Legal entity responsible for the study

Dejan Juric


Susan Eid Tumor Heterogeneity Initiative


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.